Home › Research › Tau biomarkers
Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration
Kapaki E, Paraskevas GP, Papageorgiou SG, Bonakis A, Kalfakis N, Zalonis I, Vassilopoulos D.. Alzheimer disease and associated disorders, 2008-01-01
Topic: Brain proteins, microglia and lab models
Background Cerebrospinal fluid (CSF) biomarkers have been increasingly studied in dementia clinical and differential diagnosis. Methods We assessed levels of total tau protein (tauT), tau phosphorylated at threonine 181 (tau P-181), and beta-amyloid1-42 (A beta 42) in 34 patients with frontotemporal lobar degeneration (FTLD), 76 Alzheimer disease (AD) cases, and 93 controls (CTRL). Double sandwich enzyme-linked immunosorbent assays (Innogenetics) were used for measurements.
Key findings
- Methods We assessed levels of total tau protein (tauT), tau phosphorylated at threonine 181 (tau P-181), and beta-amyloid1-42 (A beta 42) in 34 patients with frontotemporal lobar degeneration (FTLD), 76 Alzheimer disease (AD) cases, and 93 controls (CTRL).
- Double sandwich enzyme-linked immunosorbent assays (Innogenetics) were used for measurements.
- Results Total tau was significantly increased and A beta 42 decreased in FTLD and AD patients as compared with CTRL.
- CSF tau P-181 levels were significantly increased only in AD.
Why it matters
This study compared cerebrospinal fluid tau and beta-amyloid levels in patients with frontotemporal lobar degeneration, Alzheimer disease and controls to see how well they help tell the diseases apart. It is a diagnostic study and does not test any treatment, cure or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants34
- Effect size86.7%; 80.6%; 95.7%
- Evidence strengthLow
How this study scored 39/100
Published in a peer-reviewed journal. Scored zero for study design and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer disease and associated disorders) |
| Journal's citation record | 1 / 4 | Alzheimer Disease & Associated Disorders: journal h-index 131 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2008 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 34 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 59 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 3.0 citations a year over 20 year(s) since 2008 |
| Impact for its field and year | 3 / 6 | Cited 4.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Demetris Vassilopoulos: h-index 13 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Eginition Hospital: institution h-index 168 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 18317246) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1097/wad.0b013e3181610fea
- PubMed: 18317246
- Original source →
- Free full text: DSpace - NTUA (National Technical University of Athens) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Kapaki, E., Paraskevas, G. P., Papageorgiou, S. G., Bonakis, A., Kalfakis, N., Zalonis, I., et al. (2008). Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer disease and associated disorders. https://doi.org/10.1097/wad.0b013e3181610fea
Vancouver
Kapaki E, Paraskevas GP, Papageorgiou SG, Bonakis A, Kalfakis N, Zalonis I, et al. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer disease and associated disorders. 2008. doi:10.1097/wad.0b013e3181610fea. PMID: 18317246.
BibTeX
@article{kapaki2008-18317246,
author = {Kapaki, E. and Paraskevas, G. P. and Papageorgiou, S. G. and Bonakis, A. and Kalfakis, N. and Zalonis, I. and Vassilopoulos, D.},
title = {{Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration}},
journal = {Alzheimer disease and associated disorders},
year = {2008},
doi = {10.1097/wad.0b013e3181610fea},
pmid = {18317246},
url = {https://doi.org/10.1097/wad.0b013e3181610fea}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Tau biomarkers
Also tagged “biomarkers”
821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.